B.G. Negev Technologies and Applications Ltd.

Other

Tel Aviv University

Cincinnati Children's Hospital Medical Center

Ben-gurion University of the Negev Research and Development Authority

Tamar Traitel

Joseph Kost

Riki Goldbart

Dan Peer

Jeffrey A Whitsett

Yana Yudilevich

Itay Rousso

Moshe Elkabets

Nitzan Marelly

Assaf Rudich

Etili Hollander

Eliz Lewis Amar

Rivka Goldbart

Giora Enden

Shani Attias

Rinat Lifshiz

Aharon (Roni) Azagury

Paul Scot Kingma

Eden Bergman

Nitsa Buaron

Provided herein methods for treating a subject suffering from a disease or a disorder associated with hyperproliferating cells, by irradiating the cells with low-frequency ultrasound at an intensity that is either below the cavitational threshold intensity for the ultrasound frequency, or is characterized by a low-frequency mechanical index below 2.5. The methods may further comprise determining an elasticity value of the cells, and adjusting the ultrasound intensity accordingly.

Low intensity ultrasound therapy

A controlled release system includes surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition includes the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

Controlled release system for pulmonary delivery of surfactant protein D

The present invention provides a complex comprising at least one phosphoinositide and at least one positively charged modified polysaccharide, pharmaceutical compositions comprising the complex, methods for treatment of a disease, disorder or condition associated with impaired phosphoinositide-mediated signaling comprising administering the complex to an subject in need, and methods for delivery of a phosphoinositide into cells, comprising contacting the cells with the complex of the invention.

Cationic polysaccharides for delivery of phosphoinositides to cells for therapeutic purpose

A complex includes RNA and a positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin. The complex can be formed into a pharmaceutical composition. The complex can be used in methods for RNA transfection, gene therapy and treatment of a disease, disorder or condition. The positively charged modified polysaccharide can be used in connection with RNA transfection into cells.

Positively charged polysaccharides for RNA transfection

Growing community of inventors

Beer Sheva, Israel

Tamar Traitel